Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Jun 2016
At a glance
- Drugs SM 88 (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Synergy Pharmaceuticals Inc; Tyme Technologies
- 01 Jun 2016 Planned number of patients changed from 18 to 50.
- 01 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2019.
- 01 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2018.